TITLE

Diagnosing metabolic syndrome in type 2 diabetes: does it matter?

AUTHOR(S)
S.H. Song; C.A. Hardisty
PUB. DATE
June 2008
SOURCE
QJM: An International Journal of Medicine;Jun2008, Vol. 101 Issue 6, p487
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Metabolic syndrome (MetS) is used as a clinical tool to identify individuals at risk of cardiovascular disease (CVD) but its clinical value in the management of type 2 diabetes mellitus (T2DM) remains uncertain. Aim: To determine the prevalence and clinical usefulness of MetS among patients with T2DM attending diabetes clinics in a large teaching hospital. Design: Prospective observational study. Methods: Prevalence of MetS was determined by using International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) definitions in relation to age, sex, diabetes duration and history of CVD. Results: A total of 390 patients were included in this study. Both IDF and NCEP-ATPIII definitions identified high prevalence of MetS in male and female patients (IDF: male vs. female, 91.7 vs. 94.8% and NCEP-ATPIII: male vs. female, 87.6 vs. 94.2%) regardless of age (below vs. above 40 yrs, ∼70–75 vs. ∼90–95% with both definitions), diabetes duration (below vs. above 5 yrs, ∼85–90 vs. 90–95% with both definitions) and history of CVD (without vs. with CVD, ∼90 vs. ∼95% with both definitions). Central obesity was common reflected by mean waist circumference of ∼113 cm regardless of age and gender. Among those who did not have IDF-defined MetS, ∼60% had at least two CVD risk factors. Both definitions similarly classified ∼94% of the patients as either having or not having MetS. Discussion: Both definitions can be used interchangeably to diagnose MetS. However, the clinical usefulness of MetS is debatable given the very high prevalence of this condition in T2DM.
ACCESSION #
33044662

 

Related Articles

  • Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes. Goodarzi, Mark O.; Psaty, Bruce M. // JAMA: Journal of the American Medical Association;11/5/2008, Vol. 300 Issue 17, p2051 

    The authors reflect on the use of glucose lowering to control macrovascular disease in type 2 diabetes. They suggest that research conducted on patients with type 2 diabetes suggests that glycemic control is associated with the prevention of microvascular complications. They argue that any...

  • Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes. Schulze, Matthias B.; Shai, Iris; Rimm, Eric B.; Li, Tricia; Rifai, Nader; Hu, Frank B. // Diabetes;Feb2005, Vol. 54 Issue 2, p534 

    Adiponectin, predominantly synthesized in the adipose tissue, seems to have substantial anti-inflammatory properties and to be a major modulator of insulin resistance and dyslipidemia, mechanisms that are associated with an increased atherosclerotic risk in diabetic patients. However, it is...

  • Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease. Siren, Reijo; Eriksson, Johan G.; Vanhanen, Hannu // BMC Public Health;2012, Vol. 12 Issue 1, p631 

    Background: Abdominal obesity is a more important risk factor than overall obesity in predicting the development of type 2 diabetes and cardiovascular disease. From a preventive and public health point of view it is crucial that risk factors are identified at an early stage, in order to change...

  • Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Wong, S. P. Y.; Huda, M.; English, P.; Bargiotta, A.; Wilding, J. P. H.; Johnson, A.; R. Corrall; Pinkney, J. H. // Diabetologia;Dec2005, Vol. 48 Issue 12, p2641 

    Aims/hypothesis: Familial partial lipodystrophy (FPLD) and obesity are both associated with increased risks of type 2 diabetes and cardiovascular disease. Although adipokines have been implicated, few data exist in subjects with FPLD; therefore we investigated a family with FPLD due to a lamin...

  • Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus. Gami, Apoor S.; Smith, Steven A. // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p43 

    The article cites a research study, which reported that atorvastatin reduced malor cardiovascular disease events in type 2 diabetes mellitus. The researchers concluded that in patients with type 2 diabetes mellitus, atorvastatin reduced major cardiovascular disease events. It reported that The...

  • High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study. van den Brom, Charissa E.; Bulte, Carolien S. E.; Kloeze, B. Margreet; Loer, Stephan A.; Boer, Christa; Bouwman, R. Arthur // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p74 

    Background: Glucose intolerance is a major health problem and is associated with increased risk of progression to type 2 diabetes mellitus and cardiovascular disease. However, whether glucose intolerance is related to impaired myocardial perfusion is not known. The purpose of the present study...

  • Polycystic ovary syndrome and female reproduction. Elghblawi, Ebtisam // British Journal of Nursing;10/11/2007, Vol. 16 Issue 18, p1118 

    Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. The presentation is diverse. There is no single, unified definition of PCOS, no single diagnostic test and no consensus on the diagnostic criteria. Currently, PCOS is most commonly defined by the...

  • Atorvastatin did not prevent cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis.  // ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p7 

    This article reports on a study conducted to examine the efficacy of atorvastatin in preventing cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis. 1255 patients 18 to 80 years of age with type 2 diabetes who had been receiving maintenance hemodialysis for...

  • Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study. Fu, Alex Z.; Ying Qiu; Radican, Larry; Yin, Donald D.; Mavros, Panagiotis // Cardiovascular Diabetology;2010, Vol. 9, p15 

    Background: Although there is a growing body of evidence showing that patients with type 2 diabetes mellitus (T2DM) have poor glycemic control in general, it is not clear whether T2DM patients with pre-existing cardiovascular diseases (CVD) are more or less likely to have good glycemic control...

  • Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial. Klijs, Bart; Otto, Suzie J.; Heine, Robert J.; van der Graaf, Yolanda; Lous, Jan J.; de Koning, Harry J. // BMC Public Health;2012, Vol. 12 Issue 1, p671 

    Background: We describe the design and present the results of the first year of a population-based study of screening for type 2 diabetes in individuals at high risk of developing the disease. High risk is defined as having abdominal obesity. Methods: Between 2006 and 2007, 79,142 inhabitants of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics